CORT תחזית צמיחת רווחים לשנה הבאה corcept.com

Corcept Therapeutics (CORT) relies on the high margins of mifepristone and outsourced production. The projected change in earnings per share for the coming year demonstrates the market consensus, where the 113.20 mark reflects the latest data. A reputation as an endocrinology innovator is complemented by a strong team of biochemists and experts in bringing orphan drugs to market, ensuring stable business development.

This indicator measures the market's weighted average expectation for earnings per share in the next period, determining the asset's fair value through future cash flows. By analyzing this chart of the EPS n+1 consensus forecast trend, an investor assesses the stability of Corcept Therapeutics (CORT), where patent protection for endocrine drugs guarantees predictable income and minimizes the risk of overpaying for the business.